Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centre Hospitalier Régional Universitaire De Nancy has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units. HUMPHRIES, NICHOLAS ADAM is the busiest examiner, with 1 pending matter.
The two pending matters occupy separate examiner and art-unit assignments. Counsel can coordinate the portfolio’s technical presentation while addressing the procedural and substantive treatment in each record independently. HUMPHRIES, NICHOLAS ADAM handles 1 pending matter, so the available data does not identify a dominant examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18870062 | PROCESS FOR THE OBTENTION OF INVARIANT NATURAL KILLER T CELLS | HUMPHRIES, NICHOLAS ADAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18870062 | PROCESS FOR THE OBTENTION OF INVARIANT NATURAL KILLER T CELLS | HUMPHRIES, NICHOLAS ADAM | — |
| 18609297 | MESENCHYMAL STEM CELLS OBTAINED FROM WHARTON'S JELLY FOR THE TREATMENT OF SEPSIS | VAN BUREN, LAUREN K | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18870062 | PROCESS FOR THE OBTENTION OF INVARIANT NATURAL KILLER T CELLS | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18609297 | MESENCHYMAL STEM CELLS OBTAINED FROM WHARTON'S JELLY FOR THE TREATMENT OF SEPSIS | VAN BUREN, LAUREN K | 1638 | §103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Régional Universitaire De Nancy has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nicholas Adam Humphries has the most, with 1 of Centre Hospitalier Régional Universitaire De Nancy's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
